17.01.2023 - SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) - Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster presentation of the design and rationale of a Phase 1 . Seite 1
Post-hoc analysis of DISCOVER-2 Phase 3 data suggest active psoriatic arthritis patients with week 8 response to TREMFYA showed meaningful improvements in.
The rapid spread of influenza virus worldwide is driving the demand for the development of efficient influenza vaccine. Increasing clinical trials for new product development by market players
/PRNewswire/ DelveInsight s Influenza Pipeline Insight 2022 report provides comprehensive global coverage of available, marketed, and pipeline influenza.
A randomized controlled trial showed that RenalGuard is no better than conventional IV hydration at preventing contrast-induced nephropathy in high-risk patients.